产品名称
美沙拉嗪, European Pharmacopoeia (EP) Reference Standard
storage temp.
2-8°C
InChI
1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
SMILES string
Nc1ccc(O)c(c1)C(O)=O
InChI key
KBOPZPXVLCULAV-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
mesalamine, mesalazine
manufacturer/tradename
EDQM
mp
275-280 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... ALOX5(240), PPARG(5468), PTGS1(5742), PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
No data available
flash_point_c
No data available
A B Hawthorne et al.
Alimentary pharmacology & therapeutics, 27(12), 1157-1166 (2008-04-04)
Significant number of patients with ulcerative colitis (UC) fail to comply with treatment. To review issues surrounding medication non-adherence in inflammatory bowel disease (IBD), including the clinical and health service implications in the UK, and discuss strategies for optimizing medication
Alexander C Ford et al.
The American journal of gastroenterology, 106(12), 2070-2077 (2011-09-07)
Maintenance therapy with 5-aminosalicylates (5-ASAs) is recommended in patients with quiescent ulcerative colitis (UC), but compliance rates are low. Once-daily dosing may improve adherence, but impact on the relapse of disease activity is unclear as no previous meta-analysis has studied
M S Harris et al.
Alimentary pharmacology & therapeutics, 33(9), 996-1009 (2011-03-10)
The use of topical therapy in the treatment of ulcerative colitis has declined in recent years despite evidence of good efficacy. To review US prescription trends for 5-aminosalicylic acid (5-ASA) since the US approval of Asacol extended-release oral mesalazine (mesalamine)
A Lyakhovich et al.
Alimentary pharmacology & therapeutics, 31(2), 202-209 (2009-11-07)
Mesalazine (mesalamine) (5-ASA) is considered an anti-inflammatory drug for the treatment of inflammatory bowel disease. It is well tolerated by most patients and induces mucosal healing specifically in ulcerative colitis. Besides its anti-inflammatory properties, 5-ASA has been studied for cancer
John K Marshall et al.
The Cochrane database of systematic reviews, (1)(1), CD004115-CD004115 (2010-01-22)
5-Aminosalicylates (5-ASA) are considered a first-line therapy for inducing and maintaining remission of mild to moderately active ulcerative colitis (UC). When inflammation in UC is limited to the distal colon, 5-ASA can also be administered rectally as a suppository, enema
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持